Carole Longson, PhD
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued guidance supporting approval for ribociclib (Kisqali) and palbociclib (Ibrance) for patients with hormone receptor-positive/HER2¬-negative locally advanced or secondary breast cancer.
Both CDK4/6 inhibitors are indicated for use with an aromatase inhibitor (AI). If approved for routine National Health Service (NHS) use, about 8000 newly diagnosed patients in the United Kingdom would be eligible for treatment with the CDK4/6 inhibitors. Ribociclib is produced by Novartis and palbociclib is a Pfizer product.
... to read the full story